The AUGUSTUS study eagerly addressed crucial missing components of the RE-DUAL PCI, PIONEER AF-PCI and ENTRUST-AF PCI trials by performing comparisons within the triple antithrombotic regimens (apixaban plus P2Y12 inhibitor vs. VKA plus P2Y12 inhibitor) and the dual antithrombotic regimens (apixaban plus DAPT vs. VKA plus DAPT). This evidence concerns the gene P2RY12 and atrial fibrillation.